Abstract: FR-PO018
Serum Procalcitonin as a Predictor for the Development of AKI in Critically Ill Patients
Session Information
- AKI: Clinical, Outcomes, Trials - I
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 102 AKI: Clinical, Outcomes, and Trials
Authors
- Chun, Kayeong, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
- Kim, Ae jin, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
- Ro, Han, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
- Chang, Jae Hyun, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
- Lee, Hyun Hee, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
- Chung, Wookyung, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
- Jung, Ji Yong, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
Background
Procalcitonin (PCT) has been recognized as one of useful markers for the diagnosis of systemic inflammatory response syndrome. In addition, it has been reported that PCT is affected by renal function. However, there are few studies regarding the relationships between PCT and the development of acute kidney injury (AKI). Hence, we investigated whether serum PCT levels at the time of admission can predict the development of AKI and clinical outcomes.
Methods
We retrospectively analyzed data of 790 patients in whom PCT were measured on admission to the intensive care unit. We attempted to investigate that the serum PCT level at the time of admission could be as a predictor for development of AKI according to the groups classified in to the septic and the non-septic patients and risk factor for all-cause mortality.
Results
The serum PCT levels were significantly higher in patients with AKI than in those without AKI (P < 0.001). After adjustment of confounding factors, PCT still remained an independent risk factor for AKI (odds ratio [OR], 2.096; 95% confidence intervals [CI], 1.378–3.190; P = 0.001). The OR (95% CI) for AKI development among those with and without sepsis were 2.620 (1.230–5.582, P = 0.013) and 1.928 (1.119–3.321, P = 0.018), respectively.
Conclusion
Serum PCT level could be used as a marker to predict the possibility of AKI in critically ill patients admitted to the ICU.